Analytical Method Development and Validation for Simultaneous Determination of Cabotegravir and Rilpivirine Using RP-HPLC

Type I HIV can be treated by the combination of these drugs. An accurate, precise, and novel RP-HPLC technique was developed and validated for concurrent assessment of cabotegravir and rilpivirine in bulk and medicinal formulation. The separation was achieved by Waters 2695 HPLC system that comprised of PDA detector. Mobile phase was in the ratio of (70:30 v\v) acetonitrile and 0.1N potassium di hydrogen phosphate. Flow rate of 1 ml\min was employed. The detector wavelength was at 257nm.The run time was 5 minutes. The R2 value for cabotegravir was observed to be y=7596.9x+1542.1 and for rilpivirine it was y=7517.8x+5409. LOD values for cabotegravir and rilpivirine were observed to be 0.25 µg/ml and 1.79 µg/ml respectively. LOQ values for cabotegravir and rilpivirine were found to be 0.77 µg/ml and 5.44 µg/ml respectively. The suggested approach was demonstrated to be precise, exact, and ideal for use in quality control laboratories for the quantifiable examination of dosage forms, both singular and mixed.